Clin Oncol | Volume 6, Issue 1 | Case Report | Open Access

A Novel MET Exon 14 Skipping Mutation Well Responses to Crizotinib in Lung Adenocarcinoma

Chenyi Zhao, Xia Wang, Jieqing Tang, Wenjie Wang and Feng Guo^*

Department of Oncology, Nanjing Medical University, China

^*Correspondance to: Feng Guo 

Abstract

MET skipping mutation well responses to crizotinib in lung adenocarcinoma: We report the case of a 68-year-old non-smoker male patient who was diagnosed in February 2019 with a stage IV lung adenocarcinoma. Considering that he was diagnosed with bladder cancer in 2001 and gastric cancer in 2011, the chemotherapy regimen of permetrexil plus oxaliplatin was suspended. In order to probe into the genomic profile of the tumor for targeted therapy, the tissue specimen and the related blood sample were subjected to NGS analysis, and a MET exon 14 skipping mutation (c.3026_3028+11del) was identified. The patient began treatment with crizotinib 250 mg twice a day. After one month of therapy, the tumor volume significantly narrowed (-98%).

Keywords:

Crizotinib; Lung adenocarcinoma; Mesenchymal-to-Epithelial Transition (MET); Skipping mutation

Citation:

Zhao C, Wang X, Tang J, Wang W, Guo F. A Novel MET Exon 14 Skipping Mutation Well Responses to Crizotinib in Lung Adenocarcinoma. Clin Oncol. 2021;6:1799..